美国 · 股市与财经 · Reuters Business

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis

来源：Reuters Business · 美国 13 小时前

Australia's CSL said on Monday it had entered into an agreement with Switzerland-based Alentis Therapeutics to ‌co-develop and co-promote a treatment for rare kidney and liver…

在 Reuters Business 阅读全文登录后可收藏

MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.reuters.com)

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis

推荐阅读

They survived World War II and lost decades, but not 2026. Japan's century-old businesses are disappearing at a record pace

Zcash gets a Washington lobbyist to push crypto policy

Air Force removes all bombers from British base and redeploys them to the U.S. after a planned terror attack linked to Iran was foiled

Fuel Price Shock Pushes Global Gas Car Sales Below 50% for First Time

P.&G.’s Chief on Whether Brand Loyalty Is Enough When Prices Keep Climbing

Sam Altman said 'the world should accept some bad things happening' for the benefits of AI

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis

分享

推荐阅读

They survived World War II and lost decades, but not 2026. Japan's century-old businesses are disappearing at a record pace

Zcash gets a Washington lobbyist to push crypto policy

Air Force removes all bombers from British base and redeploys them to the U.S. after a planned terror attack linked to Iran was foiled

Fuel Price Shock Pushes Global Gas Car Sales Below 50% for First Time

P.&G.’s Chief on Whether Brand Loyalty Is Enough When Prices Keep Climbing

Sam Altman said 'the world should accept some bad things happening' for the benefits of AI